Hims & Hers Health, Inc. is a publicly traded telehealth company (NYSE: HIMS) that operates a weight-loss platform alongside its older hair-loss, ED, and mental-health businesses. Hims' weight-loss service in April 2026 looks materially different than it did six months earlier. The compounded semaglutide product that drove most of the company's GLP-1 growth through 2024 and into 2025 is gone, replaced by a brand-name lineup built around the Wegovy Pill, the Wegovy Pen, Ozempic, Mounjaro, Zepbound, and generic liraglutide. The pivot followed an FDA warning letter and a Department of Justice referral, both naming Hims directly.12
That is a lot to price in. The new model is cleaner on federal regulatory exposure than the old one, but the dust has not fully settled.
Key Takeaways
- The real monthly cost of a Wegovy Pen through Hims is $348, not the advertised $199. Medication is $199 per month; a separately billed Hims Weight Loss Membership is $149 per month after a $39 introductory month, and medication is not available without the membership.1
- On September 9, 2025, the FDA issued two warning letters to Hims & Hers Health, Inc., one to the Hims brand (MARCS-CMS 716567) and one to the Hers brand (MARCS-CMS 716825), citing false or misleading marketing claims on compounded semaglutide products. This is the most material federal regulatory signal among any compounded-GLP-1 telehealth provider we have reviewed.23
- Hims stopped selling compounded GLP-1 drugs on March 9, 2026. The current lineup is FDA-approved Wegovy Pill, Wegovy Pen, Ozempic, Mounjaro, Zepbound, and generic liraglutide only. Existing compounded-prescription customers should confirm transition terms and refund terms for any pre-paid multi-month plans directly with the Hims care team, because neither is published on the hims.com marketing page.4
- BBB: A+ letter grade, accredited since February 22, 2018, with 3,792 total complaints recorded on the business profile. Complaint volume reflects 12 years of operation across multiple product lines (weight loss, hair, ED, mental health), not the weight-loss business alone.5
- Trustpilot: 3.0 of 5 across 7,794 reviews. This is the largest independent feedback base of any compounded-or-former-compounded GLP-1 telehealth provider we have reviewed, and it is the lowest average. Cancellation and billing complaints are the dominant negative pattern.6
Pros and cons at a glance
A scannable summary of what Hims does well as of April 2026 and what to weigh carefully. Each point is expanded below.
Pros
- Brand-name FDA-approved GLP-1s (Wegovy Pill, Wegovy Pen, Ozempic, Zepbound, Mounjaro) plus generic liraglutide, as of April 2026
- Wegovy Pen at $348 per month all-in is within a dollar of NovoCare Direct's $349 cash-pay price, with telehealth convenience layered on top
- Wegovy Pill at $298 per month all-in is the cheapest brand-name oral semaglutide path currently available
- Twelve years in business, publicly traded, BBB-accredited since 2018
- HSA/FSA eligible with receipt submission per Hims' own FAQ
- Insurance not required; cash-pay model with no insurance paperwork
Watch for
- Two FDA warning letters issued September 9, 2025, citing false or misleading compounded semaglutide marketing by name
- DOJ referral announced by FDA/HHS in February 2026 over compounded oral semaglutide
- 3.0 of 5 Trustpilot average across 7,794 reviews, lower than Henry Meds or Mochi Health
- Dual-subscription billing structure: the $149 membership and medication are billed as two separate recurring charges, the same structure that drives complaints against Mochi Health
- Lilly's Zepbound and Mounjaro at $1,899 per month is retail list price, not a telehealth discount
- Legacy compounded-pill customers who signed up during the January 2026 launch are in a transition window; refund and continuation terms are not clearly published
What the pivot means for Hims customers
Through 2024 and into 2025, Hims sold compounded semaglutide as its main weight-loss offering at rates that started around $49 to $79 per month. That product is gone. The federal regulatory sequence that produced the current brand-name lineup is short, and the customer-facing outcome is clear.
On September 9, 2025, the FDA's Center for Drug Evaluation and Research issued two warning letters on the same day, one to Hims (MARCS-CMS 716567) and a companion letter to Hers (MARCS-CMS 716825). Both cited claims on the respective websites as false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. The Hims letter named "Same active ingredient as Ozempic and Wegovy" and "Clinically proven ingredients" as the specific misbranding; the Hers letter named "Weekly injectable GLP-1 with the same active ingredient as Ozempic and Wegovy." The FDA position was that compounded products are not FDA-approved and that claims implying equivalence to approved products misbrand the product.23
In early February 2026, FDA and HHS announced planned legal action against Hims over the compounded oral semaglutide pill and referred the company to the Department of Justice. On March 9, 2026, Hims formally agreed to stop advertising compounded GLP-1 drugs on its platform and in its marketing, and to sell FDA-approved brand-name Ozempic and Wegovy at prices matching other telehealth platforms.4
That is the arc that produced the pricing page at hims.com today. The compounded semaglutide that historically priced under $100 per month is gone. In its place is a brand-name distribution channel priced roughly at parity with NovoCare Direct, plus Lilly's products at retail list price, plus generic liraglutide at $299 per month. Customers who pre-paid for a multi-month compounded plan before the March 2026 pivot should confirm transition and refund terms directly with the Hims care team, because those terms are not documented on the current marketing page.
What Hims actually costs in April 2026
Hims publishes six weight-loss medications on its primary landing page, each with a "From" monthly price that covers medication only. An active Hims Weight Loss Membership is required on top, and it is billed as a separate recurring subscription. The membership is $39 for the first month and auto-renews at $149 per month after that.1 The real monthly cost is medication plus membership.
| Medication | Medication Price | Real Monthly Cost | Closest Comparable |
|---|---|---|---|
| Wegovy Pill (oral semaglutide 25 mg) | From $149/mo | $298/mo | Cheapest brand-name oral semaglutide path |
| Wegovy Pen (injectable) | From $199/mo | $348/mo | NovoCare Direct cash-pay $349/mo |
| Ozempic | From $199/mo | $348/mo | Retail list around $1,027/mo |
| Generic Liraglutide | From $299/mo | $448/mo | Daily injection; older drug class |
| Mounjaro | $1,899/mo | $2,048/mo | Retail list around $1,080/mo |
| Zepbound | $1,899/mo | $2,048/mo | LillyDirect vials from $299/mo |
The Wegovy Pen comparison is where the Hims model makes the most sense on its own terms. At $348 per month all-in, a Hims Wegovy Pen customer pays $1 less than the NovoCare Direct standard cash-pay price of $349 per fill, and gets Hims' care-team access and in-app dosing support for the difference. Both channels dispense the same FDA-approved product from the same manufacturer.7
The Wegovy Pill at $298 per month all-in is the more aggressive offer. Wegovy Pill is the newest FDA-approved formulation on the market, and Hims is the largest direct-to-consumer channel for it outside NovoCare Direct. The $149-per-month medication price is a notable discount on the pill's retail channel.
Lilly's products at Hims are priced at list. A patient seeking Zepbound should go through LillyDirect Self Pay Journey Program ($299 to $449 per month in vials) or use a manufacturer savings card with commercial insurance, not Hims. Hims' Zepbound and Mounjaro at $1,899 per month appear to exist on the page as a lineup completeness item, not a competitive offer.
The September 2025 FDA warning letters
This section documents the most material federal regulatory signal in our review set. No other provider we have reviewed has an FDA warning letter naming them directly. Both Henry Meds and Mochi Health have clean FDA Warning Letters Database records as of their respective review dates. Hims has two letters, same day, same subject.
The letters were issued by the FDA's Center for Drug Evaluation and Research (CDER) and addressed to Andrew Dudum, Chief Executive Officer, at Hims & Hers Health, Inc.'s San Francisco headquarters. Delivery method was electronic mail with a read receipt requested. The letters cite specific claims appearing on hims.com and forhers.com in August 2025. Per the Hims letter:2
"Your website offers various compounded drug products, including semaglutide. As described below, your claims concerning your compounded semaglutide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act, resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA."
The identified claims were "Same active ingredient as Ozempic and Wegovy" and "Clinically proven ingredients." The Hers letter cited a parallel claim on forhers.com: "Weekly injectable GLP-1 with the same active ingredient as Ozempic and Wegovy." The FDA position is that compounded products are not FDA-approved, and claims that imply equivalence with approved products are therefore misbranding under statute.3
The letters required a written response within 15 working days and warned that failure to address violations could result in seizure, injunction, or other legal action. Hims stopped selling compounded semaglutide in the months that followed and formally agreed to stop advertising compounded GLP-1 drugs on its platform and in its marketing on March 9, 2026.4
This is important context for the current lineup. The Hims that sells Wegovy Pen at $199 today is operating under a federal enforcement spotlight that was not present when the earlier compounded products were listed. That federal scrutiny is a reason to read any Hims marketing page conservatively in 2026.
What 7,794 Trustpilot reviewers and 3,792 BBB complaints actually say
Hims has the largest independent patient feedback base of any GLP-1-active telehealth provider we have reviewed. It also has the lowest average score. The gap between the BBB A+ letter grade and the 3.0 of 5 Trustpilot average deserves a direct look.
BBB. The Better Business Bureau lists Hims & Hers Inc. as BBB-accredited since February 22, 2018, operating out of 2269 Chestnut Street, San Francisco. The letter grade is A+, years in business is 12, and the total complaints recorded on the business profile is 3,792. BBB's rating methodology weights responsiveness to complaints heavily. Hims is an accredited BBB business, which typically means it agrees to a complaint-resolution process that the BBB considers satisfactory. The A+ grade does not mean there are few complaints. It means a large volume of complaints has been systematically responded to and closed.5
Trustpilot. The TrustScore for hims.com is 3.0 of 5 based on 7,794 reviews as of February 27, 2026. For comparison, Henry Meds carries 4.5 across 12,320 reviews, and Mochi Health's own marketing references approximately 4.0 across 12,900 reviews. The Hims Trustpilot profile has reviews going back multiple years and covers the full Hims product line, not only weight loss.6
The A+ BBB with 3,792 complaints alongside a 3.0 Trustpilot feels inconsistent until you read the underlying data. Hims' BBB-accredited status means complaints are formally closed through a BBB-mediated process, which keeps the letter grade high. Trustpilot captures patient sentiment closer to the transaction itself, which is frequently unhappy. The dominant negative patterns on both platforms, across reviews and complaints, center on unexpected auto-renewal charges, difficulty cancelling, and the dual-subscription structure where membership charges continue after patients believe they have cancelled medication.
The dual-subscription billing structure
Hims' weight-loss checkout separates the membership from the medication, and both are recurring charges that renew independently. The membership is $39 for the first month and $149 per month thereafter. The medication is billed separately on its own cadence. Cancelling one does not cancel the other.1
This is structurally the same billing model that drives the dominant complaint pattern against Mochi Health, where membership charges continuing after patients believe they have cancelled medication is the most common BBB complaint theme.8 Hims' larger BBB complaint volume (3,792 versus Mochi's 1,296) partly reflects Hims' broader product line and longer operating history, but reviewer accounts across Trustpilot suggest the billing-structure complaint pattern is similar.
Hims does not prominently disclose the dual-subscription structure on its primary landing page. The pricing footnote is limited to: "Price includes medication only, if prescribed. An active Hims Weight Loss Membership is required ($39 for the first month, auto-renews at $149/month thereafter). Membership is billed separately and does not include or guarantee a prescription."1 Patients who cancel medication in a customer-service chat but not the membership can continue to be billed the $149 per month until they also cancel the membership on its own.
What we recommend
Our current call on Hims is to wait roughly six months before signing up new, unless one specific offer actively makes sense for you.
The most attractive offer Hims publishes is the Wegovy Pill at $298 per month all-in. If your prescriber recommends oral semaglutide and you do not have commercial insurance coverage, the Hims pathway is the cheapest direct-to-consumer channel for this product currently published. The Wegovy Pen at $348 per month all-in is within a dollar of the NovoCare Direct standard cash-pay rate and adds in-app support in exchange.
Every other option on the Hims page has a better channel. Lilly's Zepbound and Mounjaro at $1,899 are retail list price; LillyDirect Self Pay Journey Program single-dose vials start at $299 per month. Generic liraglutide at $299 per month medication-only is a daily injection of an older drug class with smaller weight-loss effect than semaglutide or tirzepatide; patients in 2026 with access to the newer molecules typically do not choose liraglutide. Ozempic through Hims at $348 per month all-in assumes a Type 2 diabetes indication, in which case commercial insurance coverage is usually the cheaper path.
If you do decide to sign up for Hims, start on the month-to-month plan, not the $39 introductory rate. Calendar both the membership and medication renewal dates, confirm cancellation of each in writing separately, and take screenshots of any cancellation confirmation. Save the "Orders" tab receipts for FSA/HSA reimbursement. Ask which compounding pharmacy (if any) or dispensing pharmacy fills your prescription. Read the pre-checkout disclosure on pricing closely, because the $39 first-month rate is a loss-leader and the $149 monthly recurring charge starts on day 31.
The reason to wait six months is simpler. Hims as of April 23, 2026 is 45 days removed from a DOJ referral and a pivot of its entire compounded product line. Customer-experience data on the new brand-name-only model does not exist yet. The September 2025 FDA warning letter is fresh. A publicly traded company under active federal scrutiny has different incentives than one that is not, and the next quarterly earnings cycle will show how Hims balances those incentives. Either Hims settles into a cleaner brand-name distribution model with fewer complaints, or it does not. Six months of visible operation under the new model is enough to tell.
Frequently Asked Questions
Does Hims still sell compounded semaglutide in 2026?
No. Hims stopped selling compounded GLP-1 drugs on March 9, 2026 following an FDA warning letter and a Department of Justice referral. The current Hims weight-loss lineup is FDA-approved brand-name medications (Wegovy Pill, Wegovy Pen, Ozempic, Mounjaro, Zepbound) plus generic liraglutide.
What is the real monthly cost of a Wegovy Pen through Hims?
The advertised Wegovy Pen price is from $199 per month, but that is medication only. An active $149 per month Hims Weight Loss Membership is separately required. Total real cost after the first month is $348 per month. That is roughly equivalent to the $349 standard cash-pay price for a Wegovy Pen through NovoCare Direct.
Did Hims receive an FDA warning letter?
Yes. On September 9, 2025, the FDA issued two warning letters to Hims & Hers Health, Inc., one to the Hims brand (MARCS-CMS 716567) and one to the Hers brand (MARCS-CMS 716825). Both letters cited false or misleading marketing claims on compounded semaglutide products, including that the compounded products contained the same active ingredient as Ozempic and Wegovy. The letters were issued by CDER.
What happens if I'm an existing Hims compounded-prescription customer?
Hims stopped selling compounded GLP-1 drugs on March 9, 2026. Existing compounded-prescription customers have been transitioned to the brand-name lineup (Wegovy Pill, Wegovy Pen, Ozempic, Zepbound, Mounjaro, or generic liraglutide). If you pre-paid for a multi-month compounded plan before the pivot, ask your Hims care team directly about refund terms or transition credit, because those terms are not published on the current hims.com marketing page. Document any conversation in writing and screenshot the care-team chat.
How does Hims compare to Henry Meds or Mochi Health?
Hims, Henry Meds, and Mochi Health operate on different models in April 2026. Hims sells FDA-approved brand-name medications roughly priced at $298 to $448 per month all-in. Henry Meds and Mochi Health continue to sell compounded semaglutide and tirzepatide at $178 to $297 per month all-in. Henry Meds and Mochi Health both have cleaner FDA warning-letter records than Hims. The Hims Trustpilot average across more than 7,794 reviews (3.0 of 5) is lower than either Henry Meds (4.5) or Mochi Health (approximately 4.0). See our Henry Meds review and Mochi Health review for full detail on each.
Is Hims BBB-accredited?
Yes. Hims & Hers Inc. has been BBB-accredited since February 22, 2018. The business profile shows an A+ letter grade, 12 years in business, and 3,792 total complaints recorded on the profile as of March 2, 2026. BBB accreditation and the A+ grade reflect complaint-resolution responsiveness rather than low complaint volume.
How we researched this review
Every specific numerical or factual claim was verified live against a primary source in the drafting session. Pricing comes from a Wayback Machine snapshot of hims.com/weight-loss retrieved April 23, 2026. BBB data comes from a March 2, 2026 Wayback snapshot of the Hims & Hers Inc. BBB business profile. Trustpilot data comes from a February 27, 2026 snapshot of the hims.com Trustpilot profile. The FDA warning letters were retrieved directly from fda.gov on April 23, 2026. The March 9, 2026 pivot date and DOJ-referral context were sourced from CNBC coverage retrieved via Wayback Machine on April 23, 2026. Full retrieval dates are recorded in the Sources section below.
We do not take affiliate payments, sponsorship, or directed coverage in exchange for editorial content. To suggest a provider for review or report a factual error, email editorial@healthymealsincentives.org. Corrections are reviewed within five business days.
Written By
Rachel Nguyen, MS, RDN
Rachel is a registered dietitian with over a decade of experience in nutrition policy and the economics of health. Her current editorial focus covers GLP-1 medications, obesity medicine, and the intersection of nutrition and pharmaceutical treatment. She holds a Master of Science in Nutrition from the University of North Carolina.
Expert Reviewer
Dr. Kevin Park, PhD
Dr. Park is a nutrition education researcher focused on federal nutrition programs and dietary outcomes. His work has been published in the Journal of School Health and the Journal of the Academy of Nutrition and Dietetics. He reviewed the regulatory and clinical claims in this article. Clinical decisions about GLP-1 therapy should be made with a licensed prescriber.
Sources
- Hims & Hers Health, Inc. Weight Loss Care for Men, Built to Last. hims.com/weight-loss. Full product lineup retrieved via Wayback Machine snapshot dated April 1, 2026: Wegovy Pill from $149/mo, Wegovy Pen from $199/mo, Ozempic from $199/mo, Mounjaro $1,899/mo, Zepbound $1,899/mo, Generic Liraglutide from $299/mo. Hims Weight Loss Membership footnote: "An active Hims Weight Loss Membership is required ($39 for the first month, auto-renews at $149/month thereafter). Membership is billed separately and does not include or guarantee a prescription." FSA/HSA disclosure and transfer-from-other-GLP-1 language from the same FAQ section. Retrieved .
- US Food and Drug Administration. Warning Letter to Hims & Hers Health, Inc. dba Hims - MARCS-CMS 716567 - 09/09/2025. fda.gov warning letter 716567. Addressed to Andrew Dudum, CEO, Hims & Hers Health, Inc., 2269 Chestnut St., #523, San Francisco, CA 94123. Issuing office: Center for Drug Evaluation and Research (CDER). Cited claims on hims.com compounded semaglutide products: "Same active ingredient as Ozempic and Wegovy" and "Clinically proven ingredients." Determined false or misleading under FDCA sections 502(a) and 502(bb), misbranding products introduced into interstate commerce in violation of section 301(a). Retrieved .
- US Food and Drug Administration. Warning Letter to Hims & Hers Health, Inc. dba Hers - MARCS-CMS 716825 - 09/09/2025. fda.gov warning letter 716825. Companion letter issued the same day to the Hers brand. Cited claim on forhers.com: "Weekly injectable GLP-1 with the same active ingredient as Ozempic and Wegovy." Same CDER issuing office, same statutory basis, same 15-working-day response requirement. Retrieved .
- CNBC coverage of the Hims brand-name pivot, February and March 2026. cnbc.com, March 9, 2026 (Anniek Bao) for the March 9, 2026 pivot date and settlement terms (Hims agreed to stop advertising compounded GLP-1 drugs and to sell brand-name Ozempic and Wegovy at prices matching other telehealth platforms). cnbc.com, February 9, 2026 (Annika Kim Constantino and Erin Doherty) for the Friday February 6, 2026 FDA/HHS announcement of planned legal action and Department of Justice referral over the compounded oral semaglutide pill. Both retrieved via Wayback Machine .
- Better Business Bureau. Hims & Hers Inc. Business Profile. bbb.org Hims & Hers Inc.. BBB Rating: A+. BBB-accredited since February 22, 2018. Years in business: 12. Complaints total on profile: 3,792. Category: Health and Medical Products. Address: 2269 Chestnut St #523, San Francisco, CA 94123-2600. Retrieved via Wayback Machine snapshot of March 2, 2026; retrieval date .
- Trustpilot. HIMS Reviews. trustpilot.com/review/hims.com. TrustScore 3.0 of 5 across 7,794 reviews per the embedded business-unit JSON payload (displayName HIMS, identifyingName hims.com, trustScore 3, numberOfReviews 7794). Retrieved via Wayback Machine snapshot dated February 27, 2026; retrieval date .
- Novo Nordisk Inc. Wegovy Cost & Coverage Information. wegovy.com. NovoCare Pharmacy standard cash-pay $349 per month for Wegovy pens at 0.25 mg through 2.4 mg dose strengths. Wegovy list price $1,349.02 per package at retail. Retrieved .
- Healthy Meals Incentives. Mochi Health Review 2026. healthymealsincentives.org/mochi-health-reviews/. Dual-subscription billing structure comparison: Mochi Health's membership and medication are billed as two separate auto-renewing subscriptions, which drives the dominant BBB complaint pattern across 1,296 complaints in three years. Published .